GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Intangible Assets

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Intangible Assets : $0.12 Mil (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Clinuvel Pharmaceuticals's intangible assets for the quarter that ended in Dec. 2023 was $0.12 Mil.


Clinuvel Pharmaceuticals Intangible Assets Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Intangible Assets Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.13 0.14 0.13 0.12

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.13 0.13 0.12 0.12

Clinuvel Pharmaceuticals Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Clinuvel Pharmaceuticals  (OTCPK:CLVLF) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Clinuvel Pharmaceuticals Intangible Assets Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

Positive final results in stroke

By GuruFocusNews GuruFocusNews 05-04-2022

CLINUVEL Expands Pharmaceutical Portfolio

By Don Li2 Don Li2 11-08-2021

CLINUVEL Trial Results Show Drug Reduces DNA Damage

By Stock market mentor Stock market mentor 01-16-2023

CLINUVEL progresses innovative DNA Repair Program

By Marketwired Marketwired 09-10-2020

US FDA Review for SCENESSE® Extended by Three Months

By Marketwired Marketwired 06-03-2019

FDA Approves SCENESSE® For Genetic Disorder

By Marketwired Marketwired 10-09-2019

CLINUVEL delivers second positive financial result

By Marketwired Marketwired 08-29-2018

CLINUVEL Opens VALLAURIX R&D Centre In Singapore

By Marketwired Marketwired 08-31-2020

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

By Stock market mentor Stock market mentor 02-02-2023

US FDA sets PDUFA date for SCENESSE®

By Marketwired Marketwired 01-10-2019